What is William Blair's Estimate for ZVRA FY2026 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for Zevra Therapeutics in a report released on Wednesday, November 13th. William Blair analyst S. Corwin forecasts that the company will earn $0.54 per share for the year. William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.63) per share.

ZVRA has been the subject of a number of other research reports. Roth Mkm lifted their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a report on Friday, October 11th. JMP Securities began coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, Maxim Group lifted their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $21.00.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock traded down $0.41 during midday trading on Friday, reaching $8.62. 1,369,032 shares of the company were exchanged, compared to its average volume of 548,353. The firm's 50-day simple moving average is $7.97 and its 200-day simple moving average is $6.44. Zevra Therapeutics has a 1 year low of $4.18 and a 1 year high of $9.21. The company has a market capitalization of $453.57 million, a price-to-earnings ratio of -4.58 and a beta of 1.93. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. During the same quarter in the prior year, the firm earned ($0.15) earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company's stock valued at $9,883,000 after purchasing an additional 58,866 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics during the 1st quarter worth about $64,000. Jacobs Levy Equity Management Inc. grew its position in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock valued at $201,000 after purchasing an additional 17,557 shares during the last quarter. Bank of New York Mellon Corp increased its position in Zevra Therapeutics by 10.7% during the second quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company's stock worth $1,080,000 after acquiring an additional 21,231 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Zevra Therapeutics by 17.9% during the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company's stock valued at $279,000 after acquiring an additional 8,619 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.